Ezra Cohen, MD of the University of California at San Diego discusses how the EGFR monoclonal antibody, Nimotuzumab, differ from cetuximab and panitumumab and If it’s likely to play a therapeutic role in SCCHN at ASTRO Head and Neck Symposium 2016.
Advertisement